

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|---|--|--|---|
| (51) International Patent Classification ⁶ : C12Q 1/00 | | A1 | (11) International Publication Number: WO 99/55902 |
| | | | (43) International Publication Date: 4 November 1999 (04.11.99) |
| (21) International Application Number: PCT/US99/09366 (22) International Filing Date: 29 April 1999 (29.04.99) (30) Priority Data: 60/083,418 29 April 1998 (29.04.98) US (71) Applicant (for all designated States except US): UNIVERSITY OF SOUTH FLORIDA [US/US]; 4202 Fowler Avenue, FAO 126, Tampa, FL 33620 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): TABIBZADEH, Siamak [US/US]; 71 Parkview Drive, Searingtown, NY 11507 (US). (74) Agent: KOHN, Kenneth; Kohn & Associates, Suite 410, 30500 Northwestern Highway, Farmington Hills, MI 48334 (US). | | (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, ÜG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments. | |

(54) Title: DIAGNOSTIC MARKERS OF HUMAN FEMALE INFERTILITY

(57) Abstract

There is provided a method for diagnosing endometrial irregularities particularly infertility by screening an endometrial sample or bodily fluid for the presence of ebaf. Also provided is a diagnostic tool for determining the presence of endometrial irregularities screens a sample for the presence of ebaf. A contraceptive containing an effective amount of ebaf and a pharmaceutically acceptable carrier is also provided. Additionally, a diagnostic kit for timing conception is provided having a screening tool for screening a sample for the present of ebaf. Also provided is a method of treating endometrial irregularities by down-regulating the expression of ebaf.

